Dermira Inc (DERM) : Monashee Investment Management scooped up 100,000 additional shares in Dermira Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 125,965 shares of Dermira Inc which is valued at $4,189,596.Dermira Inc makes up approximately 6.41% of Monashee Investment Management’s portfolio.
Other Hedge Funds, Including , Palisade Capital Managementnj reduced its stake in DERM by selling 49,179 shares or 30.2% in the most recent quarter. The Hedge Fund company now holds 113,671 shares of DERM which is valued at $3,780,697. Dermira Inc makes up approx 0.16% of Palisade Capital Managementnj’s portfolio. Huntington National Bank added DERM to its portfolio by purchasing 43 company shares during the most recent quarter which is valued at $1,478.Magee Thomson Investment Partners reduced its stake in DERM by selling 134 shares or 81.21% in the most recent quarter. The Hedge Fund company now holds 31 shares of DERM which is valued at $983. Simplex Trading added DERM to its portfolio by purchasing 11,284 company shares during the most recent quarter which is valued at $355,559. Dermira Inc makes up approx 0.04% of Simplex Trading’s portfolio.Hamilton Lane Advisors boosted its stake in DERM in the latest quarter, The investment management firm added 22,229 additional shares and now holds a total of 34,615 shares of Dermira Inc which is valued at $1,001,758. Dermira Inc makes up approx 0.47% of Hamilton Lane Advisors’s portfolio.
Dermira Inc closed down -0.9 points or -2.79% at $31.36 with 1,25,017 shares getting traded on Monday. Post opening the session at $32.28, the shares hit an intraday low of $31.2 and an intraday high of $32.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 42 from a previous price target of $38 .
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.